Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue

 Top 20 Oncology Companies Based on 2020 Oncology Segment Revenue
  • Oncology is a rapidly evolving therapy area and all of the top Biopharma players are investing in the research and development of cancer therapies. In 2020, the world witnessed a major acquisition of Immunomedic by Gilead of $21B for Trodelvy
  • Our team at PharmaShots has compiled a list of top 20 oncology companies based on their 2020 oncology revenue
  • In in the list of top 20 companies, BMS secured the top position with total revenue of $28B from oncology segment in 2020, followed by Roche and Merck with $26B & $15B

Oncology Segment Revenue: $0.23B

Founding Year: 1984

Market Cap: $11.03B

Total Employees: 22,739

Headquarter: Hyderabad, India

Stock Exchange: NSE

Dr.Reddy is an Indian Pharmaceutical company that is mainly involved in developing a wide range of generic formulations and proprietary products. The company focuses on multiple therapeutic areas including oncology, cardiovascular, dermatology, gastrointestinal, diabetology, pain management, and nephrology. In September 2020, Dr. Reddy’s Laboratories launched Faslodex (fulvestrant) injection which is used to treat metastatic breast cancer. The company generated a sale of $0.23B from its oncology segment in 2020.

Oncology Segment Revenue: $0.30B

Founding Year: 2010

Market Cap: $32.58B

Total Employees: 5,100

Headquarter:  Beijing, China

Stock Exchange: HKG

BeiGene is a global biotechnology company that focuses mainly on developing medicines for cancer treatment. In June 2020, BeiGene reported EMA’s acceptance of its marketing authorization application for Brukinsa (zanubrutinib) for the treatment of patients with Waldenstrom’s Macroglobulinemia. In 2020, BeiGene’s key drug, Brukinsa generated total sales of $0.04B and the company generated total revenue of $0.30B from the oncology segment.

Oncology Segment Revenue: $0.39B

Founding Year: 2005

Market Cap: $49.86B

Total Employees: 16,033

Headquarter: Tokyo, Japan

Stock Exchange: TYO

Daiichi Sankyo is a global pharmaceutical company that focuses on developing novel therapies in therapeutic areas including oncology and rare diseases. In May 2020, Daiichi Sankyo launched Enhertu in Japan for patients with metastatic breast cancer. In 2020, the company’s key drug, Trastuzumab deruxtecan (Enhertu) generated total sales of $0.39B.

Oncology Segment Revenue: $0.51B

Founding Year: 2000

Market Cap: $100.88B

Total employees: 94,066

Headquarter: Brentford, United Kingdom

Stock Exchange: LON

GlaxoSmithKline (GSK) is a British multinational pharmaceutical company that focuses on developing therapies in areas including oncology, respiratory, and immuno-inflammation. In August 2020, FDA approved GSK’s Blenrep for the treatment of patients with relapsed or refractory multiple myeloma. With its two approved drugs, Zezula and Blenrep, GSK generated total revenue of $0.51B from its oncology segment in 2020.

Oncology Segment Revenue: $0.67B

Founding Year: 1987

Market Cap: $89.26B

Total Employees: 13,600

Headquarter: California, United States

Stock Exchange: NASDAQ

Gilead Sciences is an American biopharmaceutical company that focuses on researching and developing medicines in areas including HIV/AIDS, oncology, liver diseases, and hematology, inflammatory and respiratory. In October 2020, Gilead Sciences acquired Immunomedics. Gilead’s oncology drug, Yescarta recorded total sales of $0.56B in 2020. The company generated total revenue of $0.67B from its oncology segment in 2020.

Oncology Segment Revenue: $0.97B

Founding Year: 1973

Market Cap: $126.55B

Total Employees: 99,412

Headquarter: Paris, France

Stock Exchange: EPA

Sanofi is a French multinational pharmaceutical company that focuses on developing novel therapies for oncology, cardiovascular, neurology, immunology, and inflammation. In June 2020, European Commission approved Sarclisa (isatuximab) for adults with relapsed and refractory multiple myeloma. Sanofi’s leading oncology drug, Jevtana recorded sales of $0.65B last year. In 2020, Sanofi generated total revenue of $0.97B from its oncology segment.

Oncology Segment Revenue: $1.68B

Founding Year: 1863

Market cap: $55.01B

Total Employees: 99,538

Headquarter: Leverkusen, Germany

Stock Exchange: ETR

Bayer is a German multinational pharmaceutical company with a focus on cancer, cardiovascular, and kidney diseases. In March 2020, Nubeqa received EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer. Bayer’s leading drug, Nexavar recorded total sales of $0.78B last year. In 2020, Bayer generated total revenue of $1.68B from its oncology segment.

Oncology Segment Revenue: $2.06B

Founding Year: 1991

Market Cap: $16.50B

Total Employees: 1,773

Headquarter: Delaware, United States

Stock Exchange: NASDAQ

Incyte is an American multinational pharmaceutical company that focuses on multiple therapeutic areas including oncology, inflammation and autoimmunity. In May 2020, the US FDA approved Tabrecta (capmatinib) for the treatment of patients with metastatic NSCLC with METex14. The leading oncology drug of the company, Jakafi recorded total sales of $1.93B while the total revenue of the company is $2.06B from its oncology segment.

Oncology Segment Revenue: $3.76B

Founding Year: 1781

Market Cap: $54.41B

Total Employees: 47,099

Headquarter: Tokyo, Japan

Stock Exchange: TYO

Takeda is a Japanese multinational pharmaceutical company that develops innovative therapies in areas including oncology, rare diseases, and gastroenterology. In May 2020, the US FDA approved Takeda’ Alunbrig as a 1L treatment for patients diagnosed with a rare and serious form of lung cancer. Last year, the company generated total revenue of $3.76B from its oncology segment.

Oncology Segment Revenue: $4.47B

Founded Year: 2005

Market cap: $32.57B

Total Employees: 15,455

Headquarter: Tokyo, Japan

Stock Exchange: TYO

Astellas Pharma is a Japanese multinational pharmaceutical company that focuses on developing novel therapies for therapeutic areas including oncology, nephrology, urology, and transplantation. In 2020, Astellas acquired Audentes Therapeutics, and its product, Xtandi received Xtandi’s approval in NMPA for the treatment of non-mCRPC. Xtandi (lead drug) contributes 90% of the total oncology segment i.e $4.14B whereas Astellas generated total revenue of $4.47B from the oncology segment.

Oncology Segment Revenue: $5.31B

Founding Year: 1876

Market Cap: $243.78B

Total Employees: 34,960

Headquarter: Indiana, United States

Stock Exchange: NYSE

Eli Lilly is an American pharmaceutical company that deals in oncology, endocrinology, neurodegenerative diseases, immunology, pain, and migraine. In 2020, Selpercatinib (Retevmo) was granted accelerated approval by the FDA for thyroid and lung cancer. Alimta, the leading candidate of the company recorded total sales of $2.33B whereas the total revenue oncology segment is $5.31B in 2020

Oncology Segment Revenue: $6.65B

Founding Year: 2013

Market Cap: $195.03B

Total Employees: 47,000

Headquarter: Illinois, United States

Stock Exchange: NYSE

Abbvie is an American pharmaceutical company that focuses on developing novel products for therapeutic areas including oncology, immunology, dermatology, and virology. In 2020, Venclexta received FDA approval for AML and Imbruvica recorded total sales of $5.31B. Last year, Abbvie generated total revenue of $6.65B from its oncology segment.

Oncology Segment Revenue: $8.32B

Founding Year: 1980

Market Cap: $125.42B

Total Employees: 24,300

Headquarter: California, United States

Stock Exchange: NASDAQ

Amgen is an American biopharmaceutical company that is working on multiple therapeutic areas including oncology, neurology, immunology, nephrology, and inflammation. In December 2020, FDA approved Riabni, a biosimilar to Rituxan, for the treatment of adult patients with NHL & CLL. Amgen’s key drug, Xgeva recorded total sales of $1.89B while the company generated total revenue of $8.32B from its oncology segment.

Oncology Segment Revenue: $10.85B

Founding Year: 1999

Market Cap: $181.52B

Total Employees: 76,100

Headquarter: Cambridge, United Kingdom

Stock Exchange: NASDAQ

AstraZeneca is a multinational pharmaceutical and biotechnology company that focuses on a portfolio of products in areas including oncology, cardiovascular, gastrointestinal, infection, respiratory, and inflammation. In September 2020, AZ’sImfinzi was approved in the EU for 1L treatment of adults with ES-SCLC. Last year, Tagrisso recorded total sales of $4.32B while the company’s total revenue is $10.85B from its oncology segment.

Oncology Segment Revenue: $10.86B

Founding Year: 1849

Market Cap: $262.11B

Total Employees: 78,500

Headquarter: New York, United States

Stock Exchange: NYSE

Pfizer is an American multinational pharmaceutical and biotechnology company that develops novel medicines and vaccines for therapeutic areas including oncology, immunology, cardiology, endocrinology and neurology. In June 2020, the EU approved Bavencio as a treatment for patients with LA or metastatic urothelial carcinoma. Pfizer’s leading drug, Ibrance recorded 50% of the total sales of the company in the oncology segment i.e. $5.39B.

Oncology Segment Revenue: $12.36B

Founding Year: 1887

Market Cap: $452.52B

Total Employees: 134,500

Headquarter: New Jersey, United States

Stock Exchange: NYSE

Johnson and Johnson is an American multinational pharmaceutical company that has a product portfolio of multiple therapeutic areas including CV, oncology, immunology, and endocrinology. In its oncology segment, J&J focuses on core diseases including prostate cancer and multiple myeloma. The company’s leading drug, Darzalex recorded total sales of $4.19B whereas the total revenue is $12.36B in the oncology segment.

Oncology Segment Revenue: $14.71B

Founding Year: 1996

Market Cap: $222.98B

Total Employees: 105,794

Headquarter: Basel, Switzerland

Stock Exchange: SWX

Novartis is a Swiss multinational pharmaceutical company that works in multiple disease areas including oncology, hepatology, immunology, dermatology, musculoskeletal diseases, neuroscience, and ophthalmology. In 2020, Novartis generated total revenue of $14.71B from its oncology segment.

Oncology Segment Revenue: $15.83B

Founding Year: 1891

Market Cap: $190.76B

Total Employees: 74,000

Headquarter: New Jersey, United States

Stock Exchange: NYSE

Merck is an American multinational pharmaceutical company focused on developing innovative medicines in areas including oncology, infectious diseases, respiratory and immunology. In 2020, FDA approved Merck’ Keytruda in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer. Keytruda recorded total sales of $14.38B whereas the total revenue of the company is $15.83B in its oncology segment.

Oncology Segment Revenue: $26.37B

Founding Year: 1896

Market Cap: $380.16B

Total Employees: 101,465

Headquarter: Basel, Switzerland

Stock Exchange: SWX

Roche is a Swiss multinational pharmaceutical company focused on developing products in areas including oncology, immunology, and ophthalmology, cardiovascular and respiratory. In December 2020, EC approved Roche’ Phesgo for people with HER2- breast cancer. Roche’s Avastin recorded total sales of $5.64B whereas the company generated total revenue of $26.37B from its oncology segment.

Oncology Segment Revenue: $28.14B

Founding Year: 1887

Market Cap: $144.86B

Total Employees: 30,250

Headquarter: New York, United States

Stock Exchange: NYSE

BMS is a global biopharmaceutical company focused on developing innovative products in oncology, immunology, and hematology, cardiovascular. In November 2020, BMS received EC’s approval for Opdivo + Yervoy with two cycles of CT for 1L treatment of mNSCLC. BMS’ Revlimid recorded total sales of $12.10B while the company generated total revenue of $28.14B from its oncology segment.

Source: Company annual reports, SEC filings, press releases, and company websites

Market Cap source: Google finance (as of 09th September 2021)

All revenues are reported in USD.

Related Post: Top 20 Oncology Companies by Total Products

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post